naltrexone has been researched along with glutamine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Grandy, DK; Hjorth, SA; Schwartz, TW; Thirstrup, K | 1 |
| Butour, JL; Meunier, JC; Moisand, C; Mollereau, C; Parmentier, M | 1 |
| Jung, YC; Namkoong, K | 1 |
2 review(s) available for naltrexone and glutamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; gamma-Aminobutyric Acid; Glutamine; Humans; Models, Biological; Models, Neurological; N-Methylaspartate; Naltrexone; Narcotic Antagonists; Neurons; Polymorphism, Genetic; Receptors, Opioid, mu; Recurrence; Taurine | 2006 |
3 other study(ies) available for naltrexone and glutamine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Analysis of selective binding epitopes for the kappa-opioid receptor antagonist nor-binaltorphimine.
Topics: Amino Acid Sequence; Animals; Epitopes; Glutamine; Molecular Sequence Data; Naltrexone; Rats; Receptors, Opioid, kappa; Receptors, Opioid, mu; Recombinant Fusion Proteins | 1995 |
Replacement of Gln280 by His in TM6 of the human ORL1 receptor increases affinity but reduces intrinsic activity of opioids.
Topics: Adenylyl Cyclase Inhibitors; Animals; Binding, Competitive; Cell Membrane; CHO Cells; Cricetinae; Diprenorphine; Dynorphins; Etorphine; Fentanyl; Glutamine; Histamine; Humans; Kinetics; Ligands; Naltrexone; Narcotic Antagonists; Narcotics; Nociceptin; Nociceptin Receptor; Opioid Peptides; Receptors, Opioid | 1996 |